Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MANISH SHARMA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1790819332
CMS profile
1126262
Location
GRAND RAPIDS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,855.50

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,837.50 2
Food and Beverage $18.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Aadi Bioscience, Inc. $1,837.50 2
Novartis Pharmaceuticals Corporation $18.00 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MANISH SHARMA

NPI 1790819332 · CMS profile ID 1126262

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

GRAND RAPIDS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790819332?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790819332?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790819332?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1790819332?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $1,855.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Aadi Bioscience, Inc. $1,312.5009/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250853033 CMS
Novartis Pharmaceuticals Corporation $18.0007/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200524770 CMS
Aadi Bioscience, Inc. $525.0007/29/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250853011 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $659.76 21
PY2020 $185.35 5
PY2021 $23.93 1
PY2022 $558.49 34
PY2023 $1,123.71 47
PY2024 $773.90 11
PY2025 $1,855.50 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $373.20 2
PY2025 Principal investigator $4,235,582.65 823
PY2024 Recipient $4,269.33 9
PY2024 Principal investigator $3,811,534.65 643
PY2023 Recipient $3,810.00 6
PY2023 Principal investigator $3,149,687.09 471
PY2022 Principal investigator $3,302,171.04 339
PY2021 Recipient $7,293.02 4
PY2021 Principal investigator $2,076,760.51 208
PY2020 Recipient $7,900.00 2
PY2020 Principal investigator $1,132,655.23 78
PY2019 Principal investigator $1,305,040.24 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

80 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,837.35 12/31/2020 Non-covered Recipient Entity
Cancer And Hematology
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 736742645
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,413.29 12/31/2020 Non-covered Recipient Entity
Cancer & Hematology Centers Of Western Michigan
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 736746761
Principal investigator 1 Merck Sharp & Dohme Corporation $19,541.97 12/29/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740731727
Principal investigator 1 Merck Sharp & Dohme Corporation $473.22 12/29/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740731733
Principal investigator 1 Merck Sharp & Dohme Corporation $26,000.00 12/28/2020 Non-covered Recipient Entity
START MIDWEST
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 740705243
Principal investigator 1 Eli Lilly and Company $15,723.00 12/22/2020 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC
A PHASE 1 MULTICENTER GLOBAL FIRST IN HUMAN STUDY OF THE CD73 INHIBITOR LY3475070 AS MONOTHERAPY OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES No dispute reported 06/30/2026 728739511
Recipient PFIZER INC. $3,200.00 12/16/2020 Covered Recipient Physician ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742856435
Principal investigator 1 GlaxoSmithKline, LLC. $44,153.00 12/15/2020 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734913073
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 12/15/2020 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734920453
Principal investigator 1 Merck Sharp & Dohme Corporation $795.60 12/11/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740731681
Principal investigator 1 Merck Sharp & Dohme Corporation $9,975.76 12/09/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740731683
Principal investigator 1 GlaxoSmithKline, LLC. $2,728.00 12/08/2020 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734926613
Recipient Eli Lilly and Company $4,700.00 12/07/2020 Covered Recipient Physician A PHASE 1 MULTICENTER GLOBAL FIRST IN HUMAN STUDY OF THE CD73 INHIBITOR LY3475070 AS MONOTHERAPY OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES No dispute reported 06/30/2026 728722025
Principal investigator 1 Exelixis Inc. $675.00 12/03/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736579027
Principal investigator 1 Exelixis Inc. $4,765.50 12/03/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736579029
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 12/02/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740731731
Principal investigator 1 Merck Sharp & Dohme Corporation $525.80 12/02/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740731735
Principal investigator 1 Epizyme, Inc., $26,050.00 11/30/2020 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 748604611
Principal investigator 1 PFIZER INC. $21,000.00 11/21/2020 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 742896081
Principal investigator 1 PFIZER INC. $21,000.00 11/21/2020 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 742912689
Principal investigator 1 Epizyme, Inc., $1,770.00 11/13/2020 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 748604551
Principal investigator 1 GlaxoSmithKline, LLC. $2,728.00 11/10/2020 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734925671
Principal investigator 1 Merck Sharp & Dohme Corporation $270.00 11/04/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740731677
Principal investigator 1 Merck Sharp & Dohme Corporation $635.00 11/02/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729589
Principal investigator 1 Merck Sharp & Dohme Corporation $1,080.00 11/02/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729627
Principal investigator 1 Merck Sharp & Dohme Corporation $270.00 10/28/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740731675
Principal investigator 1 Exelixis Inc. $7,070.00 10/27/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736578221
Principal investigator 1 Exelixis Inc. $300.00 10/27/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736578223
Principal investigator 1 Merck Sharp & Dohme Corporation $350.00 10/21/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740731679
Principal investigator 1 GlaxoSmithKline, LLC. $1,986.00 10/20/2020 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734917783
Principal investigator 1 Merck Sharp & Dohme Corporation $4,317.98 10/16/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729587
Principal investigator 1 Merck Sharp & Dohme Corporation $200.00 10/16/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729629
Principal investigator 1 Exelixis Inc. $300.00 10/13/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736578091
Principal investigator 1 Exelixis Inc. $15,749.10 10/08/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736578059
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 10/06/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740731729
Principal investigator 1 Merck Sharp & Dohme Corporation $8,895.23 10/01/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729591
Principal investigator 1 Exelixis Inc. $675.00 09/22/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736577381
Principal investigator 1 Exelixis Inc. $300.00 09/22/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736577477
Principal investigator 1 Exelixis Inc. $9,434.07 09/15/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736577299
Principal investigator 1 Merck Sharp & Dohme Corporation $565.75 09/08/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740731725
Principal investigator 1 Merck Sharp & Dohme Corporation $1,080.00 09/04/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729535
Principal investigator 1 Exelixis Inc. $30,059.23 09/03/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736577189
Principal investigator 1 GlaxoSmithKline, LLC. $1,364.00 09/03/2020 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734913311
Principal investigator 1 Merck Sharp & Dohme Corporation $12,550.40 09/02/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729537
Principal investigator 1 Merck Sharp & Dohme Corporation $1,327.50 09/02/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729539
Principal investigator 1 Merck Sharp & Dohme Corporation $341.70 09/01/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740731687
Principal investigator 1 GlaxoSmithKline, LLC. $1,364.00 08/27/2020 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734929585
Principal investigator 1 Merck Sharp & Dohme Corporation $19,541.97 08/25/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729581
Principal investigator 1 Merck Sharp & Dohme Corporation $7,264.00 08/24/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729611
Principal investigator 1 Exelixis Inc. $1,720.00 08/20/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576587
Principal investigator 1 Exelixis Inc. $1,670.00 08/20/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736577591
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,794.94 08/13/2020 Non-covered Recipient Entity
Cancer & Hematology Centers Of Western Michigan
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 736743211
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,643.36 08/13/2020 Non-covered Recipient Entity
Cancer And Hematology
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 736744867
Principal investigator 1 Exelixis Inc. $99,379.64 08/13/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576669
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 07/28/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729583
Principal investigator 1 Merck Sharp & Dohme Corporation $330.00 07/22/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729505
Principal investigator 1 Merck Sharp & Dohme Corporation $9,101.15 07/20/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729531
Principal investigator 1 GlaxoSmithKline, LLC. $1,364.00 06/30/2020 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734924991
Principal investigator 1 Merck Sharp & Dohme Corporation $3,740.50 06/26/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729559
Principal investigator 1 Merck Sharp & Dohme Corporation $8,398.43 06/26/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729561
Principal investigator 1 Exelixis Inc. $1,720.00 06/25/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736576029
Principal investigator 1 GlaxoSmithKline, LLC. $1,784.00 06/02/2020 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734926261
Principal investigator 1 GlaxoSmithKline, LLC. $6,208.00 05/21/2020 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734923425
Principal investigator 1 Merck Sharp & Dohme Corporation $100.00 05/20/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729555
Principal investigator 1 Merck Sharp & Dohme Corporation $13,896.39 05/20/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729557
Principal investigator 1 Merck Sharp & Dohme Corporation $1,595.00 04/22/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729491
Principal investigator 1 Merck Sharp & Dohme Corporation $25,214.92 04/22/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729493
Principal investigator 1 Merck Sharp & Dohme Corporation $3,740.50 04/22/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729519
Principal investigator 1 Merck Sharp & Dohme Corporation $735.00 04/22/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729521
Principal investigator 1 Merck Sharp & Dohme Corporation $54,000.00 04/14/2020 Non-covered Recipient Entity
START MIDWEST
An Open Label, Single Arm, Phase 1b,2 Study to Evaluate the Safety and Efficacy of Grapiprant ARY-007 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1,L1 Non-Small Cell Lung Cancer NSCLC Adenocarcinoma No dispute reported 06/30/2026 740702275
Principal investigator 1 Merck Sharp & Dohme Corporation $1,371.10 03/26/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729497
Principal investigator 1 GlaxoSmithKline, LLC. $165,037.40 03/19/2020 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734925651
Principal investigator 1 Merck Sharp & Dohme Corporation $75,783.68 03/16/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729545
Principal investigator 1 Exelixis Inc. $3,420.43 03/05/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736575371
Principal investigator 1 Merck Sharp & Dohme Corporation $27,065.60 02/27/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729547
Principal investigator 1 Merck Sharp & Dohme Corporation $22,450.72 02/14/2020 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 740729341
Principal investigator 1 Exelixis Inc. $21,443.40 02/06/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736574839
Principal investigator 1 Exelixis Inc. $12,083.72 01/14/2020 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736574705
Principal investigator 1 GlaxoSmithKline, LLC. $2,479.00 01/14/2020 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 734924055
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $102,570.05 01/03/2020 Non-covered Recipient Entity
Start Midwest
Phase I II FIH Monotherapy Nivo Combination No dispute reported 06/30/2026 736762533